/PRNewswire/ Takeda UK and Ireland is pleased to announce Seyda Atadan Memis as its new General Manager. Seyda has most recently been the General Manager of.
RTÉ Courts Reporter
The family of a woman who died from a heart attack has settled its case against the manufacturer and supplier of a defibrillator which it was claimed was not working when she became ill while at work.
The court approved the settlement of €300,000 in the case of Brendan Farrell from Hillside, Greystones Co. Wicklow whose 39-year-old wife Elaine O Keefe died on 10 October 2012 while in the canteen of her workplace.
The settlement was made without admission of liability.
In his High Court action, Mr Farrell claimed the defibrillator at Takeda Ireland Limited where Ms O Keefe worked as a manager was defective.
Takeda to create 100 new jobs over the next 3 years
Written by Robert McHugh, on 17th Feb 2021. Posted in Ireland
Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, today announced a €36 million investment in its Grange Castle facility. The investment will support the expansion of the company’s cell therapy production facility and create approximately 100 new jobs over the next three years.
The biopharmaceutical company is headquartered in Japan and focuses its R&D efforts on four therapeutic areas - Oncology, Rare Genetic and Haematology, Neuroscience, and Gastroenterology (GI). Takeda also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. The commercial scale cell therapy production facility is the first of its kind in Ireland. Following the expansion, the team at Grange Castle will play an important role in supplying European, US and Canadian markets with a cell therapy treatment option for patients.
Takeda announces expansion of stem cell therapy production facility in Ireland Investment will create approximately 100 new jobs over the next three years
Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, today announced a €36 million investment in its Grange Castle facility. The investment will support the expansion of the company’s cell therapy production facility and create approximately 100 new jobs over the next three years.
The commercial scale cell therapy production facility is the first of its kind in Ireland. Following the expansion, the team at Grange Castle will play an important role in supplying European, US and Canadian markets with a cell therapy treatment option for patients.